iShares 7-10 Year Treasury Bond ETF vs Neurocrine Biosciences Inc — how do they compare? iShares 7-10 Year Treasury Bond ETF trades at $93.12, while Neurocrine Biosciences Inc trades at $152.14 (market cap $16.46B). The key difference: Neurocrine Biosciences Inc is trading nearer its 52-week high, iShares 7-10 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| IEF | NBIX | |
|---|---|---|
52-Week High | $97.99 | $185.50 |
52-Week Low | $92.76 | $123.10 |
Market Cap | — | $16.46B |
Sector | — | Health |
Enterprise Value | — | $16.48B |
Trailing returns across standard periods
The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity of greater than or equal to seven years and less than ten years. The fund will invest at least 80% of its assets in the component securities of the underlying index, and the fund will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index.
Read more on IEF →Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →